Premium
Candida krusei mutants to study virulence and Fluconazole resistance
Author(s) -
Scorzoni Liliana,
Leite Fernanda Sangalli,
Matsumoto Marcelo Teruyuki,
Oliveira Haroldo César,
Sardi Janaína C. O.,
Benaducci Tatiane,
FuscoAlmeida Ana Marisa,
MendesGiannini Maria José Soares
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.921.5
Subject(s) - candida krusei , microbiology and biotechnology , virulence , fluconazole , mutant , biology , virulence factor , broth microdilution , biofilm , candida glabrata , wild type , antifungal , gene , bacteria , genetics , minimum inhibitory concentration , antibiotics
Candida krusei is intrinsically resistant to Fluconazole and infects mainly patients suffering from hematologic malignancies and other immunocompromised patients. We constructed mutant of Candida krusei using the Agrobacterium tumefaciens transformation technique and various approaches were developed to understand the mechanism of resistance and the virulence marker as biofilm. The Fluconazol susceptibility of the wild and mutant's strains was analyzed by microdilution test according to CLSI documents. The biofilm production and the proteomic profile of the wild type and sensible strains were also evaluated. Changes in the susceptibility of mutants strain to Fluconazol decreased in 6 folds when compared to wild type, the same strains did not produce biofilms. These results indicate that an important virulence factor may be modified. Interestingly the proteomic dates show different expression of protein support the explanation of intrinsically resistance of Candida krusei to Fluconazol. Supported by CAPES, FAPESP, FINEP and PADC‐FCF.